Compare VVOS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | CODX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 15.6M |
| IPO Year | 2020 | 2017 |
| Metric | VVOS | CODX |
|---|---|---|
| Price | $1.99 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $6.25 | $2.25 |
| AVG Volume (30 Days) | 123.1K | ★ 1.6M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,317,000.00 | $507,892.00 |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $55.64 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.76 | N/A |
| 52 Week Low | $1.98 | $0.23 |
| 52 Week High | $7.95 | $1.55 |
| Indicator | VVOS | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 42.32 |
| Support Level | $1.98 | $0.34 |
| Resistance Level | $2.28 | $0.41 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 15.31 | 1.92 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.